Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.
Read the full article on WikipediaAdvanced (unresectable or metastatic) uveal melanoma Clinical criteria: Treatment Phase: Initial treatment - day 1 Patient must have HLA-A*02:01-positive disease, AND Patient must have uveal melanoma that has been confirmed either (i) histologically, (ii) cytologically, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must not have received prior systemic therapy for metastatic disease. Population criteria: Patient must be at least 18 years of age. According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 3 doses (on Days 1, 8 and 15) and for at least 16 hours after each infusion is completed. If the patient does not experience hypotension that is Grade 2 or worse (requiring medical intervention) with the third dose, subsequent doses can be administered in an appropriate outpatient/ambulatory care setting. Supervision by a health care professional is recommended for a minimum of 30 minutes following each infusion. This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting. Positive HLA-A*02:01 assessment must be documented in the patient's medical records.
“Tebentafusp is a fusion protein consisting of the α and β chains of a T cell receptor protein targeting gp100 (PMEL, specifically the fragment presented by HLA-A*02:01) and a single-chain variable fragment targeting CD3. The former action causes the drug molecule to bind to cancer cells that present the fragment. The latter causes the drug molecule to activate T cells. The result is activation of T cells in the vicinity of cancer cells.”
Working under the parallel aged-care framework? Aged-care equivalent →